Products
Ganirelix was commercially available as a solution for injection in prefilled syringes (Orgalutran). It was approved in many countries since 2000. It was discontinued in 2019.
Structure and properties
Ganirelix is a decapeptide and a derivative of gonadotropin-releasing hormone (GnRH) produced by the hypothalamus. It differs from the natural hormone at positions 1, 2, 3, 6, 8, and 10.
Effects
Ganirelix (ATC H01CC01) inhibits the release of LH and FSH at the pituitary gland, thereby lowering estrogen concentrations. The effects are due to antagonism at GnRH receptors on the pituitary gland. In women, ganirelix delays the LH surge. Unlike GnRH agonists, administration of ganirelix does not result in an initial increase in LH and FSH levels.
Indications
For suppression of premature LH peaks in women undergoing assisted reproductive medicine.
Dosage
According to the SmPC. The drug is administered subcutaneously.
Contraindications
- Hypersensitivity
- Pregnancy and lactation
- Moderate or severe limitation of renal or hepatic function.
For complete precautions, see the drug label.
Interactions
No information on drug-drug interactions is available.
Adverse effects
The most common possible adverse effects include headache, nausea, and vaginal bleeding.